Syngene International Limited (BOM:539268)
India · Delayed Price · Currency is INR | Market Cap | 162.13B -39.0% |
| Revenue (ttm) | 36.00B -3.4% |
| Net Income | 2.21B -56.4% |
| EPS | 5.47 -56.6% |
| Shares Out | n/a |
| PE Ratio | 73.36 |
| Forward PE | 48.11 |
| Dividend | 1.25 (0.31%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 52,721 |
| Open | 398.85 |
| Previous Close | 395.35 |
| Day's Range | 398.85 - 411.70 |
| 52-Week Range | 375.50 - 678.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 501.88 (+23.3%) |
| Earnings Date | Jul 29, 2026 |
About Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, prot... [Read more]
Financial Performance
In fiscal year 2026, Syngene International's revenue was 37.39 billion, an increase of 2.64% compared to the previous year's 36.42 billion. Earnings were 3.17 billion, a decrease of -36.17%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 539268 stock is "Buy." The 12-month stock price target is ₹501.88, which is an increase of 23.30% from the latest price.
News
Syngene International Transcript: Q1 26/27
Revenue declined 16% year-over-year due to loss of a major biologics customer and client attrition, with Q1 EBITDA margin at 12%. Strategic focus is on CDMO growth, AI-led discovery, and operational efficiency, with a return to growth expected in FY 2028.
Syngene International Quarterly report: Q1 2027
Syngene International has published its Q1 2027 quarterly earnings report on July 29, 2026.
Syngene International Slides: Q1 2027
Syngene International has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 29, 2026.
Syngene appoints Siddharth Mittal as Managing Director and CEO
Syngene International, a prominent global contract research, development, and manufacturing organisation (CRDMO), has announced the appointment of Siddharth Mittal as its new Managing Director and Chi...
Syngene International announces 12.50% final dividend for FY26
Syngene International Limited has announced a final dividend of 12.50%, equivalent to ₹1.25 per equity share of ₹10 each, for the financial year ended March 31, 2026. This recommendation was…
Top gainers in morning trade: HFCL at ₹116.03 up 8.34%, syngene international at ₹467.65 up 8.21%, gujarat fluorochemicals at ₹3,602.00 up 7.16%
The Indian stock market is experiencing a turbulent session as the Nifty 50 index slips below the 23,900 mark, currently trading at 23,997.55, down 0.74%. The Sensex also reflects this…
Syngene International Transcript: Q4 25/26
FY 2026 saw 3% revenue growth, with Q4 rebounding 13% sequentially despite Librela headwinds. FY 2027 is expected to be flat as Librela impact fades, with margins guided in the mid-20s and growth anticipated from FY 2028 as new capabilities and contracts mature.
Syngene International Quarterly report: Q4 2026
Syngene International has published its Q4 2026 quarterly earnings report on April 30, 2026.
Syngene International Slides: Q4 2026
Syngene International has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 30, 2026.
Syngene International Annual report: Q4 2026
Syngene International has published its Q4 2026 annual report on April 30, 2026.
Syngene stock jumps 8% despite profit falling 19% — the market is clearly looking past one
Syngene International delivered a weak set of fourth-quarter numbers for FY26 on Wednesday — profit fell 19%, EBITDA dropped 12% and margins contracted by 450 basis points — and yet…
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today?
Biodexa Pharmaceuticals shares are trading sharply higher Thursday afternoon after the company said it partnered with Syngene International. ... Full story available on Benzinga.com
Biodexa Pharmaceuticals Stock Surges 69% Over Partnership With Syngene International
(RTTNews) - Shares of Biodexa Pharmaceuticals Plc (BDRX) are climbing about 69 percent on Thursday morning trading after it announced a partnership with Syngene International Ltd for the manufacture o...
Syngene International shares fall sharply over 7% today: Details here
Shares of Syngene International Ltd witnessed sharp selling pressure in morning trade today, sliding more than 7% and touching a...
Syngene International Transcript: Q3 25/26
Q3 revenue declined 3% year-on-year due to a single large molecule product impact, while underlying business showed steady growth. Full-year revenue is now expected to decline 3%-5%, with the product headwind persisting into FY 2027. Research services and CDMO segments continue to expand capabilities and utilization.
Syngene International Quarterly report: Q3 2026
Syngene International has published its Q3 2026 quarterly earnings report on January 23, 2026.
Syngene International Slides: Q3 2026
Syngene International has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 23, 2026.
Syngene International extends strategic collaboration with Bristol Myers Squibb Till 2035
Syngene International has announced a major extension of its long-standing strategic collaboration with Bristol Myers Squibb, strengthening their partnership through...
Syngene International Ltd Webinar on Clinical Trials Market Call Transcript
Syngene International Ltd Webinar on Clinical Trials Market Call Transcript
Syngene International Transcript: Status Update
India's clinical research market is rapidly expanding, driven by patient diversity, regulatory improvements, and cost advantages. Syngene has scaled its clinical research capabilities, offering integrated, end-to-end services and leveraging advanced technologies, with strong profitability and no major capacity constraints. A recent global trial win highlights its growing presence.
Syngene International Slides: Status Update
Syngene International has posted slides in relation to its latest quarterly earnings report, which was published on December 17, 2025.
Syngene International Transcript: Q2 25/26
Q2 FY26 revenue grew 2% YoY to INR 911 crore, with research services outpacing CDMO, but EBITDA and PAT declined due to inventory correction and higher costs. Strategic investments in clinical trials, ADCs, and peptides position the company for future growth, with full-year guidance maintained.
Syngene International Quarterly report: Q2 2026
Syngene International has published its Q2 2026 quarterly earnings report on November 6, 2025.
Syngene International Slides: Q2 2026
Syngene International has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.
Goldman Sachs maintains buy on Syngene, bullish on FY26 early-teens growth outlook, sees 15.5% upside on Q1 beat and rising CRO-led margin gains
Goldman Sachs has retained a Buy rating on Syngene International, setting a target price of ₹775, which implies a potential upside of 15.5% from the current market price of ₹670.75. The brokerage high...